Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report

被引:5
作者
Sagawa, Tamotsu [1 ]
Sato, Yasushi [2 ]
Nagashima, Hiroyuki [1 ]
Takada, Kohichi [3 ]
Takahashi, Mamoru [4 ]
Hirakawa, Masahiro [1 ]
Hamaguchi, Kyoko [1 ]
Tamura, Fumito [1 ]
Fujikawa, Koshi [1 ]
Okamoto, Koichi [2 ]
Kawano, Yutaka [2 ]
Sogabe, Masahiro [2 ]
Miyamoto, Hiroshi [2 ]
Takayama, Tetsuji [2 ]
机构
[1] Hokkaido Canc Ctr, Dept Gastroenterol, Sapporo, Hokkaido, Japan
[2] Tokushima Univ, Dept Gastroenterol & Oncol, Grad Sch Biomed Sci, Tokushima, Japan
[3] Sapporo Med Univ, Dept Med Oncol, Sch Med, Sapporo, Hokkaido, Japan
[4] Sapporo Med Univ, Dept Resp Med & Allergol, Sch Med, Sapporo, Hokkaido, Japan
关键词
immune checkpoint inhibitor; colorectal cancer; sarcoidosis; microsatellite instability; side effects; ADVERSE EVENTS; BLOCKADE; CELLS; TH17;
D O I
10.3389/fimmu.2023.1203621
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundImmune checkpoint inhibitors (ICIs) are the standard treatment for metastatic colorectal cancer (mCRC) with high microsatellite instability (MSI-H). Among immune-related adverse events (irAEs), drug-induced sarcoidosis-like reactions (DISR) are often difficult to differentiate from cancer progression. Main Body This is a case of a woman in her mid-60s, with mCRC (RAS wild/BRAF mutant/MSI-H) and abdominal lymph node metastasis, treated with four courses of ipilimumab + nivolumab every 3 weeks, followed by nivolumab every 2 weeks as third-line treatment. After treatment, the original lymph node metastases shrank, but hilar/mediastinal lymph nodes appeared. Endoscopic ultrasound-guided fine-needle aspiration of these lymph nodes revealed multiple epithelioid granulomas without necrosis, indicating a sarcoidosis-like reaction. Fluorodeoxyglucose-positron emission tomography scan showed abnormal subcutaneous accumulation in bilateral forearms and bilateral knee joints. Biopsy of the cutaneous lesions was also performed, which revealed epithelioid granulomas. As the patient had no symptoms in other organs, no specific therapeutic intervention was administered. After the discontinuation of immunotherapy, the sarcoidosis-like reaction regressed without cancer relapse. ConclusionsClinicians should be aware of the possibility of DISR as an irAE during the ICI treatment of mCRC. In suspected cases of DISR following ICI therapy, it is important to differentiate between cancer progression and DISR through histological diagnosis for the subsequent strategy, as radiological and serological findings are not definitive.
引用
收藏
页数:6
相关论文
共 14 条
[1]  
Arrichiello Gianluca, 2021, Cancer Treat Res Commun, V28, P100442, DOI [10.1016/j.ctarc.2021.100442, 10.1016/j.ctarc.2021.100442]
[2]   Blockade of the Programmed Death-1 Pathway Restores Sarcoidosis CD4+ T-Cell Proliferative Capacity [J].
Braun, Nicole A. ;
Celada, Lindsay J. ;
Herazo-Maya, Jose D. ;
Abraham, Susannma ;
Shaginurova, Guzel ;
Sevin, Carla M. ;
Grutters, Jan ;
Culver, Daniel A. ;
Dworski, Ryszard ;
Sheller, James ;
Massion, Pierre P. ;
Polosukhin, Vasiliy V. ;
Johnson, Joyce E. ;
Kaminski, Naftali ;
Wilkes, David S. ;
Oswald-Richter, Kyra A. ;
Drake, Wonder P. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 190 (05) :560-571
[3]   Drug-Induced Sarcoidosis-Like Reactions [J].
Chopra, Amit ;
Nautiyal, Amit ;
Kalkanis, Alexander ;
Judson, Marc A. .
CHEST, 2018, 154 (03) :664-677
[4]   Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis [J].
Chorti, Eleftheria ;
Kanaki, Theodora ;
Zimmer, Lisa ;
Hadaschik, Eva ;
Ugurel, Selma ;
Gratsias, Emmanouil ;
Roesch, Alexander ;
Bonella, Francesco ;
Wessendorf, Thomas E. ;
Waelscher, Julia ;
Theegarten, Dirk ;
Schadendorf, Dirk ;
Livingstone, Elisabeth .
EUROPEAN JOURNAL OF CANCER, 2020, 131 :18-26
[5]   Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors [J].
Das, Satya ;
Johnson, Douglas B. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
[6]   PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer [J].
Dulos, John ;
Carven, Gregory J. ;
van Boxtel, Susan J. ;
Evers, Sabine ;
Driessen-Engels, Lilian J. A. ;
Hobo, Willemijn ;
Gorecka, Monika A. ;
de Haan, Anton F. J. ;
Mulders, Peter ;
Punt, Cornelis J. A. ;
Jacobs, Joannes F. M. ;
Schalken, Jack A. ;
Oosterwijk, Egbert ;
van Eenennaam, Hans ;
Boots, Annemieke M. .
JOURNAL OF IMMUNOTHERAPY, 2012, 35 (02) :169-178
[7]   Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors [J].
Gkiozos, Ioannis ;
Kopitopoulou, Alexandra ;
Kalkanis, Alexandros ;
Vamvakaris, Ioannis N. ;
Judson, Marc A. ;
Syrigos, Konstantinos N. .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) :1076-1082
[8]   Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis [J].
Le Burel, Sebastien ;
Champiat, Stephane ;
Mateus, Christine ;
Marabelle, Aurelien ;
Michot, Jean-Marie ;
Robert, Caroline ;
Belkhir, Rakiba ;
Soria, Jean-Charles ;
Laghouati, Salim ;
Voisin, Anne-Laure ;
Fain, Olivier ;
Mekinian, Arsene ;
Coutte, Laetitia ;
Szwebel, Tali-Anne ;
Dunogeant, Laetitia ;
Lioger, Bertrand ;
Luxembourger, Cecile ;
Mariette, Xavier ;
Lambotte, Olivier .
EUROPEAN JOURNAL OF CANCER, 2017, 82 :34-44
[9]   Immune-related adverse events with immune checkpoint blockade: a comprehensive review [J].
Michot, J. M. ;
Bigenwald, C. ;
Champiat, S. ;
Collins, M. ;
Carbonnel, F. ;
Postel-Vinay, S. ;
Berdelou, A. ;
Varga, A. ;
Bahleda, R. ;
Hollebecque, A. ;
Massard, C. ;
Fuerea, A. ;
Ribrag, V. ;
Gazzah, A. ;
Armand, J. P. ;
Amellal, N. ;
Angevin, E. ;
Noel, N. ;
Boutros, C. ;
Mateus, C. ;
Robert, C. ;
Soria, J. C. ;
Marabelle, A. ;
Lambotte, O. .
EUROPEAN JOURNAL OF CANCER, 2016, 54 :139-148
[10]  
Miedema J., 2021, CURR OPIN PULM MED, V27, P439, DOI [10.1097/MCP.0000000000000800, DOI 10.1097/MCP.0000000000000800]